Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Change of Adviser

7th Jan 2015 10:38

RNS Number : 5208B
ABCAM Plc
07 January 2015
 



For immediate release

7 January 2015

 

ABCAM PLC

("Abcam" or "the Company")

 

Change of Adviser

 

Abcam PLC (AIM: ABC), a global leader in the supply of life science research tools, is pleased to announce the appointment of J.P. Morgan Securities plc (which conducts its UK investment banking activities as J.P. Morgan Cazenove, "J.P. Morgan Cazenove") as the Company's nominated adviser and as joint corporate broker with immediate effect. Peel Hunt LLP will continue as joint corporate broker.

 

- Ends -

 

For further information please contact:

 

Abcam - + 44 (0) 1223 696000

Alan Hirzel, Chief Executive Officer

Jeff Iliffe, Chief Financial Officer

www.abcam.com

 

J.P. Morgan Cazenove - Nominated Advisor and Joint Corporate Broker - + 44 (0) 20 7742 4000

James Mitford / Alex Bruce - Nominated Advisor

 

Peel Hunt LLP - Joint Corporate Broker - + 44 (0) 207 418 8900

Clare Terlouw / Jock Maxwell MacDonald - Corporate Broking

 

Brunswick - + 44 (0) 20 7404 5959

Justine Mcllroy / Will Medvei / Anna Carruth

 

About Abcam plc

 

Abcam plc is a leading provider of protein research tools and services, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.

 

Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company's catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.

 

Headquartered in Cambridge, UK, Abcam has eight global subsidiary offices enabling local services and multi-language support, and sells to over 100 countries. The Company was founded in 1998, and now employs over 750 people. Abcam was admitted to AIM in 2005 (AIM: ABC).

 

To find out more, please visit www.abcam.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
APPBGGDBUXGBGUR

Related Shares:

ABC.L
FTSE 100 Latest
Value8,809.74
Change53.53